pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company's lead development product, Medidur is used for posterior of the eye (posterior uveitis). Medidur is in Phase III clinical trials. The Company's pre-clinical development program is focused on developing products using its platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat ophthalmic diseases, such as wet and dry age-related macular degeneration (AMD), glaucoma and osteoarthritis, among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon, nanostructured elemental silicon, designed to provide sustained delivery of biologic molecules, such as peptides, proteins and antibodies.